BR112021021904A2 - Preparações de fator da coagulação para liberação em tecido do trato intestinal usando um dispositivo de liberação de fármacos ingerível - Google Patents

Preparações de fator da coagulação para liberação em tecido do trato intestinal usando um dispositivo de liberação de fármacos ingerível

Info

Publication number
BR112021021904A2
BR112021021904A2 BR112021021904A BR112021021904A BR112021021904A2 BR 112021021904 A2 BR112021021904 A2 BR 112021021904A2 BR 112021021904 A BR112021021904 A BR 112021021904A BR 112021021904 A BR112021021904 A BR 112021021904A BR 112021021904 A2 BR112021021904 A2 BR 112021021904A2
Authority
BR
Brazil
Prior art keywords
clotting
cfs
capsule
delivery
preparation
Prior art date
Application number
BR112021021904A
Other languages
English (en)
Inventor
Anusha Garapaty
Anvesh Dasari
Joel Harris
A Imran Mir
Mir Hashim
Radhika Korupolu
Sara Ansaloni
Original Assignee
Rani Therapeutics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rani Therapeutics Llc filed Critical Rani Therapeutics Llc
Publication of BR112021021904A2 publication Critical patent/BR112021021904A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • A61M31/002—Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/142—Pressure infusion, e.g. using pumps
    • A61M5/14244—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body
    • A61M5/14276—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body specially adapted for implantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/31—Details
    • A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
    • A61M5/31565—Administration mechanisms, i.e. constructional features, modes of administering a dose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/31—Details
    • A61M5/32—Needles; Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
    • A61M5/3295—Multiple needle devices, e.g. a plurality of needles arranged coaxially or in parallel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/142—Pressure infusion, e.g. using pumps
    • A61M5/14244—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body
    • A61M5/14276—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body specially adapted for implantation
    • A61M2005/14284—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body specially adapted for implantation with needle insertion means
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
    • A61M2037/0023—Drug applicators using microneedles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/35—Communication
    • A61M2205/3507—Communication with implanted devices, e.g. external control
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/60—General characteristics of the apparatus with identification means
    • A61M2205/6063—Optical identification systems
    • A61M2205/6072—Bar codes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medical Informatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

preparações de fator da coagulação para liberação em tecido do trato intestinal usando um dispositivo de liberação de fármacos ingerível. modalidades fornecem dispositivos, preparações e métodos para a liberação de agentes terapêuticos (tas) como, por exemplo, fatores de coagulação (cfs), por exemplo, fator viii (fviii), incluindo peguilado e outras formas de fviii estabilizado, dentro do trato gi. muitas modalidades fornecem um dispositivo ingerível, por exemplo, uma cápsula, para a liberação de tas na parede intestinal (iw).modalidades também fornecem preparações de ta configuradas para estarem contidas dentro da cápsula, avançadas da cápsula na iw e/ou tecido circundante (st) e se degradam para liberar o ta na corrente sanguínea para produzir um efeito terapêutico (por exemplo, coagulação aumentada). a preparação pode estar acoplada operativamente a meios de liberação que possuem uma primeira configuração na qual a preparação está contida na cápsula e uma segunda configuração na qual a preparação é avançada para fora da cápsula dentro da iw ou st (por exemplo, da cavidade peritoneal). modalidades são particularmente úteis para a liberação de cfs para o tratamento de distúrbios da coagulação (por exemplo, hemofilia), em que esses cfs são pobremente absorvidos e/ou degradados dentro do trato gi.
BR112021021904A 2019-05-03 2020-05-01 Preparações de fator da coagulação para liberação em tecido do trato intestinal usando um dispositivo de liberação de fármacos ingerível BR112021021904A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962843221P 2019-05-03 2019-05-03
US201962845209P 2019-05-08 2019-05-08
PCT/US2020/031197 WO2020227162A1 (en) 2019-05-03 2020-05-01 Clotting factor preparations for delivery into tissue of the intestinal tract using a swallowable drug delivery device

Publications (1)

Publication Number Publication Date
BR112021021904A2 true BR112021021904A2 (pt) 2022-02-22

Family

ID=73050863

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021021904A BR112021021904A2 (pt) 2019-05-03 2020-05-01 Preparações de fator da coagulação para liberação em tecido do trato intestinal usando um dispositivo de liberação de fármacos ingerível

Country Status (10)

Country Link
US (1) US20220118056A1 (pt)
EP (1) EP3962516A4 (pt)
JP (1) JP2022530615A (pt)
KR (1) KR20220004148A (pt)
CN (1) CN114007638A (pt)
AU (1) AU2020270420A1 (pt)
BR (1) BR112021021904A2 (pt)
CA (1) CA3137539A1 (pt)
MX (1) MX2021013310A (pt)
WO (1) WO2020227162A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8809269B2 (en) 2010-12-23 2014-08-19 Rani Therapeutics, Llc Therapeutic agent preparations comprising insulin for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8734429B2 (en) 2010-12-23 2014-05-27 Rani Therapeutics, Llc Device, system and methods for the oral delivery of therapeutic compounds
US9402806B2 (en) 2010-12-23 2016-08-02 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9259386B2 (en) 2010-12-23 2016-02-16 Rani Therapeutics, Llc Therapeutic preparation comprising somatostatin or somatostatin analogoue for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9415004B2 (en) 2010-12-23 2016-08-16 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US10603275B2 (en) 2017-11-07 2020-03-31 Rani Therapeutics, Llc Clotting factor preparations for delivery into tissue of the intestinal tract using a swallowable drug delivery device
CN116981471A (zh) * 2021-02-24 2023-10-31 拉尼医疗有限公司 血友病a的治疗
EP4322918A1 (en) * 2021-04-13 2024-02-21 Grifols Worldwide Operations Limited Liquid composition comprising factor viii or factor viii/von willebrand factor complex
CN115300774B (zh) * 2022-08-27 2024-01-30 深圳市资福医疗技术有限公司 一种药剂递送装置、释药方法及应用其的释药胶囊

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9149617B2 (en) * 2010-12-23 2015-10-06 Rani Therapeutics, Llc Device, system and methods for the oral delivery of therapeutic compounds
EA029045B1 (ru) * 2011-07-08 2018-02-28 Байоджен Хемофилия Инк. Химерные и гибридные полипептиды фактора viii и способы их применения
US20140019297A1 (en) * 2012-07-10 2014-01-16 Bootic, Inc. Electronic Commerce System Incorporating Shopping Baskets
US10689460B2 (en) * 2014-05-15 2020-06-23 Incube Labs, Llc PCSK9 antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US11548940B2 (en) * 2014-05-15 2023-01-10 Rani Therapeutics, Llc Anti-interleukin antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
AU2016257813B2 (en) * 2015-05-01 2021-05-13 Rani Therapeutics, Llc Pharmaceutical compositions and methods for fabrication of solid masses comprising polypeptides and/or proteins
AU2016320867B2 (en) * 2015-09-08 2023-03-30 Rani Therapeutics, Llc PCSK9 antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US11046749B2 (en) * 2016-06-24 2021-06-29 Mogam Institute For Biomedical Research Chimera protein comprising FVIII and vWF factors, and use thereof
US10603275B2 (en) * 2017-11-07 2020-03-31 Rani Therapeutics, Llc Clotting factor preparations for delivery into tissue of the intestinal tract using a swallowable drug delivery device

Also Published As

Publication number Publication date
KR20220004148A (ko) 2022-01-11
US20220118056A1 (en) 2022-04-21
CN114007638A (zh) 2022-02-01
EP3962516A4 (en) 2023-01-04
MX2021013310A (es) 2022-02-11
WO2020227162A1 (en) 2020-11-12
EP3962516A1 (en) 2022-03-09
CA3137539A1 (en) 2020-10-20
JP2022530615A (ja) 2022-06-30
AU2020270420A1 (en) 2021-11-18

Similar Documents

Publication Publication Date Title
BR112021021904A2 (pt) Preparações de fator da coagulação para liberação em tecido do trato intestinal usando um dispositivo de liberação de fármacos ingerível
White et al. Ketorolac: its role as part of a multimodal analgesic regimen
BR112021017993A2 (pt) Preparações de agente terapêutico e métodos para liberação de fármacos em um lúmen do trato intestinal com o uso de um dispositivo ingerível de liberação de fármacos
BR112015004244A2 (pt) composição médica oralmente administrada
BR112015021446A2 (pt) métodos cirúrgicos empregando composições de peptídeo amfifílico purificado
WO2011112229A3 (en) Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
BR112015022067A2 (pt) método e aparato para a administração de droga a um sítio alvo
EA201101518A1 (ru) Фармацевтическая композиция для применения в медицинской и ветеринарной офтальмологии
AR057946A1 (es) Formulacion de zonisamida de liberacion sostenidda
BRPI0507609A (pt) combinações terapêuticas de anti-psicóticos atìpicos com antagonistas de fator de liberação de corticotropina
AR084816A1 (es) Metodos y medicamentos para el tratamiento de la enfermedad de alzheimer
BR112018003892A2 (pt) ?composição farmacêutica e método para a redução da gordura?
MX2021007904A (es) Preparaciones de agente terapéutico para administración en un lumen del tracto intestinal utilizando un dispositivo de administración de fármaco tragable.
JP2015524444A5 (pt)
BR112012030641A2 (pt) métodos e composições para terapia farmacêutica oral
BR102013003570A8 (pt) Composições de plasma rico em plaquetas
BR112013010829B1 (pt) Omposição farmacêutica intravenosa para proporcionar alívio da dor e/ou da inflamação
CL2013001382A1 (es) Metodo para aumentar la seguridad y la eficacia de las transfusiones de sangre, que comprende administrar a un paciente una composicion farmaceutica que comprende un copolimero de polioxietileno/polioxipropileno, en donde la composicion se mezcla con la sangre antes de la transfusion, o se administra al paciente antes o despues de la transfusion.
BR112022016100A2 (pt) Composição farmacêutica compreendendo microgrânulos de liberação sustentada incluindo análogo de glp-1 ou sal farmaceuticamente aceitável do mesmo
ES2328999B1 (es) Uso del acido maslinico para el tratamiento de patologias y sus sintomas mediante la inhibicion de cox-2.
MX2019008482A (es) Tratamiento medico que comprende administracion enteral de edaravona.
BR112017022984A2 (pt) dispositivo para facilitar o posicionamento de um cateter para administrar um medicamento em um paciente que esteja respirando espontaneamente
US9687518B2 (en) Medicament for treating muscle and skeletal diseases
BR112015010808A2 (pt) pastilha medicamentosa à base de ibuprofeno sódico di-hidratado
BR112018072177A2 (pt) composição farmacêutica, recipiente, e, métodos para tratar e prevenir congestão nasal, infecções virais do trato respiratório e/ou inflamação da garganta